drugset / Trial / NCT01492374
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly intravenous (IV) infusions of BMS-241027
Timeline
- Start
- 2012-02
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-241027 | Unknown | 0.003 mg/kg | Intravenous |
| Subject | BMS-241027 | Unknown | 0.01 mg/kg | Intravenous |
| Subject | BMS-241027 | Unknown | 0.03 mg/kg | Intravenous |